GLP-1s, Specialty Drugs, and the New Pharmacy Math for Employers

Prescription drug spending has become one of the most significant contributors to rising employer health care costs, and the composition of that spending is changing quickly. Specialty medications continue to grow as a share of total pharmacy spend, and GLP-1 therapies, originally associated with diabetes management and now widely used for weight management, have expanded into new clinical areas. Emerging oral formulations are broadening access further.

For employers, this creates a genuinely difficult problem. These are, in many cases, effective medications that improve health outcomes for the people taking them. They are also expensive, frequently used long-term, and capable of reshaping a pharmacy budget in a single plan year. Balancing access, affordability, and long-term sustainability has become one of the central benefits questions of the moment, and there is no clean answer.

Why Pharmacy Spend Is Growing So Fast

Several dynamics are compounding at once. Specialty medications, which treat complex or chronic conditions and often carry high per-prescription costs, represent a growing portion of total drug spending. At the same time, GLP-1 adoption has continued to climb, and as these therapies expand into additional clinical indications, the eligible population grows with them.

Newer oral formulations add another dimension. Easier administration tends to increase uptake, which is a genuine clinical positive for patients who benefit from treatment and a genuine budget pressure for the plan paying for it. Both things are true simultaneously, which is precisely what makes this issue hard to reduce to a simple cost-control decision.

The Access and Affordability Tension

Employers face real pressure from two directions. Restricting coverage of high-cost medications controls near-term spending but can deny employees treatment that meaningfully improves their health, with downstream consequences for the conditions those medications address. Covering everything without structure protects access but can produce pharmacy costs that force cuts elsewhere in the benefits program.

Neither extreme serves employees well. A plan that covers nothing expensive is not much of a plan. A plan that becomes unaffordable eventually gets restructured in ways nobody likes. The workable middle involves clinical oversight, thoughtful utilization management, and honest communication with employees about how decisions get made and why.

What Thoughtful Management Looks Like

Employers who are handling this well tend to share a few practices:

• Clinical appropriateness criteria. Coverage tied to documented clinical need rather than blanket approval or blanket exclusion
• Care coordination. Ensuring patients on high-cost therapies have an ongoing clinical relationship rather than a prescription in isolation
• Attention to the underlying condition. Medications work best alongside the primary care, monitoring, and lifestyle support that address root causes
• Generic and biosimilar utilization. Ensuring lower-cost clinically equivalent options are used where genuinely appropriate
• Transparent communication. Employees understand and accept structure far better when the reasoning is explained rather than imposed

The through-line is that pharmacy management works better as a clinical exercise than a purely financial one. If you want help thinking through how prescription costs interact with the rest of your benefits strategy, our team can help you look at it.

The Primary Care Connection

One underappreciated aspect of pharmacy cost management is how much it depends on primary care. Many of the conditions driving specialty and GLP-1 utilization, including diabetes, cardiovascular disease, and obesity-related conditions, are conditions where consistent primary care changes trajectories. Early identification, ongoing monitoring, and sustained management can reduce both the severity of disease and the intensity of treatment required.

An employee with a strong primary care relationship is more likely to have their condition caught early, managed appropriately, and monitored over time. An employee without one is more likely to arrive at treatment later, when the condition is more advanced and the intervention more expensive. Pharmacy spending is downstream of a great deal that happens, or fails to happen, in primary care.

Planning Rather Than Reacting

Prescription costs are not going to resolve themselves, and the trajectory suggests continued growth as these therapies expand. The employers who manage this best will be the ones who plan for it deliberately rather than treating each year's pharmacy increase as an unwelcome surprise.

That means understanding your own utilization patterns specifically, building clinical structure around high-cost therapies, and investing in the primary care foundation that influences how many employees need those therapies and how well they do on them. It is slower than a formulary change and considerably more durable.

Nothing in this article is medical advice. Decisions about prescription medications, including GLP-1 therapies and specialty drugs, should be made by patients together with a licensed clinician. Individual clinical circumstances vary.

This article is for general informational purposes only and does not constitute legal, tax, or benefits advice. Consult qualified counsel or your benefits advisor before making plan or formulary decisions.

Vital110 and VitalDirect are membership-based care programs, not insurance plans, and are not a substitute for major medical coverage or prescription drug coverage.

How Health Compass Inc. Helps

At Health Compass Inc., we help employers strengthen the primary care foundation that shapes so much of their pharmacy spending. Our Vital110 program provides zero-co-pay primary care and direct clinician access, supporting the early identification and consistent chronic disease management that influence both how many employees progress to high-cost therapies and how well those therapies work.

Talk to our team about the connection between primary care and prescription spending. You can also learn more about our employer solutions and explore our blog for more on chronic disease management.